Baxter International Inc. (BAX)

Baxter International is trading near the top of its 52-week range after a steady climb, but the stock's recent gains sit against a weak earnings picture. The price of $26.42 is 1.6% below the analysts' median 12-month target of $26.00, and the consensus rating is Hold. The stock is above its 20-day, 50-day and 200-day averages, which is the strongest part of the chart. The open question for investors is whether the business can turn a 5.00% revenue gain into profit, since the trailing GAAP loss per share is -$1.21.

The stock is up 47.68% over six months and 48.85% over the past year, and it trades 22.63% above its 200-day average. The 50-day average sits 13.80% above the 200-day average, which is the kind of spacing that shows a sustained rise rather than a single spike. The MACD line is positive and the 14-day RSI of 59.3 sits in the neutral zone, so momentum is supportive without signalling an overheated stock.

The company reported a net profit margin of -5.3% and a return on equity of -9.04%, while the sector median return on equity is 7.3%. Its operating margin of 9.88% shows the core operations earn a profit before financing and other costs, but the net result is still a loss. The debt-to-equity ratio of 1.36 adds to the balance sheet pressure. CleaRank rates company health at 2 out of 5.

At a price-to-sales ratio of 1.18, the stock is 65.3% below the sector median P/S of 3.4. That discount reflects the loss-making results rather than a bargain, because the price-to-earnings ratio is not meaningful with negative earnings. The stock's market value of $13.7B and its low beta of 0.67 against the S&P 500 place it as a less volatile holding than the market, with a typical daily move of 2.74%.

Of 15 analysts, 2 rate the stock buy or strong buy, 12 rate it hold and 1 rates it sell. Three months ago, 2 of 13 ratings were buy. On October 30, 2026, JP Morgan kept its Neutral rating and Wells Fargo kept its Equal-Weight rating. On October 7, 2026, Barclays started coverage at Underweight. Citigroup kept its Neutral rating on October 5, 2026. The median target of $26.00 is 1.6% below the price, and the range runs from $23.00 to $40.00.

The base case is that BAX holds its position above its moving averages while the company works toward profitability, with the stock trading in a range that stays close to analyst expectations. Analysts expect earnings per share to shrink 7.4% this fiscal year to $2.10 and a further 2.7% next year to $2.05, while expecting revenue to grow 4.3% to $11.7B this year. That gap between sales growth and falling earnings is the main tension. The case would improve if revenue growth keeps pace with the 5.00% of the latest quarter and margins hold near the 9.88% operating margin, which could push the stock toward the $30.00 high. The case would weaken if the price falls back through the 20-day EMA at $25.22 and the 50-day SMA at $24.52, or if the lowest analyst target of $23.00 becomes the reference point. The highest target of $40.00 belongs to one of the more optimistic analysts and is far from the consensus.

Support sits first at the 20-day EMA of $25.22, the nearest level below the price and a short-term trend line that the stock has been trading above. Below it is the 50-day SMA at $24.52, which marks where the medium-term uptrend would be tested. The 200-day SMA at $21.54 is the longer-term trend line, and the 52-week low of $15.73 is the bottom of the range. Resistance is the 52-week high of $30.00, the nearest level above the price. A move above it would be a new high for the past year.